DVA — DaVita Inc.

Market sentiment is neutral-to-cautious. Q2 2026 results were strong (revenue $3.554B, adjusted EPS $4.02, +36% YoY) and management raised FY2026 adjusted EPS guidance to $14.10-$15.20, but the stock had already rallied >60% YTD and has since pulled back with risk-off macro pressure (oil >$100, higher yields). Analyst consensus is Hold with a $235.67 average target, while the 2026-09-13 technicals show RSI 42.73 and price 11.46% below its 50-day SMA, reflecting a correction within a longer uptrend.

Revenue has grown steadily from $3.121B in Q3 2023 to $3.554B in Q2 2026, roughly a 4-5% CAGR, with Q2 2026 up 5.2% YoY. Operating margin has hovered in the mid-teens and expanded slightly to 16.1% in Q2 2026 from 15.9% in Q2 2025. Earnings have been volatile quarter-to-quarter—Q3 2025 EPS was $2.04 and Q4 2025 was $2.45—but inflected sharply upward in 2026: Q1 EPS $2.87 (+43.5% YoY) and Q2 EPS $4.02 (+55.8% YoY). TTM free cash flow reached ~$1.61B through Q2 2026, up ~25% YoY, so the recent earnings acceleration looks like a real momentum shift rather than a one-quarter blip, though it follows a soft 2025 second half.

As of 2026-09-13, DVA trades at 15.61x TTM EPS of $13.082, a premium to its 5-year average P/E of 12.79, but the forward P/E is ~12.2x using next-FY EPS of $14.845—slightly below its own historical average. PEG is 1.33, P/S 0.832 is in line with its 5-year average of 0.82, and EV/EBITDA is 8.0x. On forward earnings and cash flow, the stock looks fairly valued to modestly cheap, not expensive; the trailing premium mostly reflects depressed prior-year earnings.

The market is pricing in mid-single-digit revenue growth and roughly 13% EPS growth, not a heroic turnaround. With FY2026 guidance of $14.10-$15.20 and next-FY consensus EPS of $14.845, a 12-14x multiple supports a $170-$208 share price range; the current $181.55 sits in the middle. If Q3 2026 EPS meets the ~$3.62 consensus and guidance holds, the stock can re-rate toward $200+; if commercial payer mix or volumes disappoint, downside toward the low-$160s is plausible.

As of 2026-09-13, RSI(14) was 42.73—neutral, not oversold. Price was 1.48% above its 20-day SMA but 11.46% below its 50-day SMA and 9.78% above its 200-day SMA, so the stock is in a medium-term correction within a long-term uptrend. It has fallen from the 52-week high of $247.49 but held above the 200-day; entry timing is not urgent. A reclaim of the 50-day or stabilization near $175-$180 would improve the setup.

• Interest rates and Treasury yields: DVA carries ~$10.66B of long-term debt, so higher yields raise refinancing and interest costs and pressure leveraged equities.
• Reimbursement regulation: Medicare/Medicaid rate changes, ACA premium tax credits, and commercial payer mix are critical to dialysis economics; commercial reimbursement disproportionately drives profit.
• Labor and input cost inflation: clinical staffing shortages and wage pressure can compress margins in a labor-intensive care model.
• Macro risk-off/geopolitical: oil above $100 and elevated geopolitical tensions have pressured broad equities and rotated capital away from some healthcare names.
• Value-based care shift: growth of Integrated Kidney Care and partnerships like Humana's are a structural tailwind, but execution and payer adoption remain uncertain.

• Q3 2026 earnings on October 28, 2026, with consensus EPS around $3.62 and a potential guidance update.
• Execution on the Humana value-based care partnership covering 10,000+ chronic kidney disease members and expansion of Integrated Kidney Care.
• Continued share repurchases; DVA bought back 2.2M shares at an average $154.95 in Q2 2026.
• Clarity on 2026 Medicare reimbursement rates and ACA exchange effectuation.
• Progress on 2030 Community Care Commitments and commercial value-based arrangements.

• High leverage and negative equity: long-term debt of $10.66B and stockholders' equity of -$765M at 2026-06-30; debt/equity ratios are distorted and the balance sheet is aggressive.
• Regulatory/reimbursement risk: dialysis is heavily government-funded, and cuts to Medicare/Medicaid or commercial payer rates would hit margins.
• Payer mix deterioration: commercial insurance drives disproportionate profit; ACA premium tax credit changes or lower exchange effectuation could reduce commercial yield.
• Labor cost inflation and staffing shortages in dialysis centers.
• Berkshire Hathaway's ~45% stake is a validation but also a concentration risk if it changes its position.

DaVita is a stable, cash-generative dialysis provider with strong Q2 2026 momentum, raised guidance, and a forward P/E around 12x, supported by ~$1.61B TTM free cash flow. But the stock has already had a huge run, sits below its 50-day SMA, carries heavy debt with negative equity, and faces real reimbursement/payer-mix risks. At $181.55 as of 2026-09-13, the risk/reward is balanced; this is a hold/neutral, not a high-conviction buy.

I applied a 14x multiple to next-FY consensus EPS of $14.845, yielding $207.83, rounded to $208. The 14x is a slight premium to DVA's 5-year average P/E of 12.79 to reflect its strong free cash flow and improved 2026 earnings momentum, but a discount to analyst targets due to high leverage, negative equity, and reimbursement/payer-mix risk.